SHANGHAI, Aug. 10, 2017 /PRNewswire/ -- CARsgen Therapeutics (CARsgen), a global leader in developing chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors, today announced its first-in-class anti-Claudin18.2-CAR-T cell therapy for gastric and pancreatic cancers has entered into phase-I clinical trial and starts patients recruitment at Changhai Hospital of Shanghai, a renowned hospital of global reputation for expertise on gastroesophageal and related cancer.